A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Sarcoidosis

In brief

The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.

Key facts

Study ID
NCT01732211
Run by
Pfizer
People needed
1
Starts
2013-03-15
Expected to finish
2013-09-23
Last updated by the study team
2020-01-06

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.